{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:05:31Z","timestamp":1789632331285,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04955-0","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:42:53Z","timestamp":1789630973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies"],"prefix":"10.1007","volume":"96","author":[{"given":"Vanessa","family":"Gonzalez-Covarrubias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Morales-Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Bonilla-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Rodr\u00edguez-Dorantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Fr\u00edas-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Soto-Perez-de-Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"4955_CR1","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","volume":"28","author":"LM Henricks","year":"2017","unstructured":"Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM (2017) DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol 28:2915\u20132922","journal-title":"Ann Oncol"},{"key":"4955_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","volume":"26","author":"VM Pratt","year":"2024","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, Turner AJ, van Schaik RHN, Whirl-Carrillo M, Weck KE (2024) DPYD genotyping recommendations: a joint consensus recommendation of multiple international pharmacogenetics consortia. J Mol Diagn 26:851\u2013863","journal-title":"J Mol Diagn"},{"key":"4955_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/OP.20.00553","volume":"16","author":"F Innocenti","year":"2020","unstructured":"Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G (2020) All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide. JCO Oncol Pract 16:793\u2013798","journal-title":"JCO Oncol Pract"},{"key":"4955_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fphar.2019.01169","volume":"10","author":"V Gonzalez-Covarrubias","year":"2019","unstructured":"Gonzalez-Covarrubias V, Morales-Franco M, Cruz-CCorrea OF, Mart\u00ednez-Hern\u00e1ndez A, Garc\u00eda-Ort\u00edz H, Barajas-Olmos F, Genis-Mendoza AD, Mart\u00ednez-Maga\u00f1a JJ, Nicolini H, Orozco L, Sober\u00f3n X (2019) Variation in actionable pharmacogenetic markers in natives and mestizos from Mexico. Front Pharmacol 10:1169","journal-title":"Front Pharmacol"},{"key":"4955_CR5","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ijc.29670","volume":"137","author":"F Bray","year":"2015","unstructured":"Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, Pi\u00f1eros M, Steliarova-Foucher E, Swaminathan R, Antoni S, Soerjomataram I, Forman D (2015) Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer 137:2060\u20132071","journal-title":"Int J Cancer"},{"key":"4955_CR6","first-page":"950","volume":"12","author":"C Farinango","year":"2022","unstructured":"Farinango C, Tejera E, Crespo N, P\u00e9rez-Castillo Y, L\u00f3pez-Cort\u00e9s A, Paz-Y-Mi\u00f1o C (2022) Genetic variations of the DPYD gene and its relationship with ancestral components in different Ecuadorian populations. Genes (Basel) 12:950","journal-title":"Genes (Basel)"},{"key":"4955_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentj\u00e9 VO, Imholz ALT, Hamberg P, Gelderblom H, Beijnen JH, Schellens JHM, Swen JJ, Guchelaar HJ (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19:1459\u20131467","journal-title":"Lancet Oncol"},{"key":"4955_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41416-024-02754-z","volume":"131","author":"TH Chan","year":"2024","unstructured":"Chan TH, Chua EW, Low SK et al (2024) DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review. Br J Cancer 131:24\u201336","journal-title":"Br J Cancer"},{"key":"4955_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/dmpt-2025-0070","volume":"41","author":"C Gonz\u00e1lez de la Cruz","year":"2025","unstructured":"Gonz\u00e1lez de la Cruz C, Rodrigues-Soares F, Guevara M, Rodr\u00edguez E, Man\u00f3chio C, Pe\u00f1as-Lled\u00f3 E, Dorado P, LLerena A (2025) Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry. Drug Metab Pers Ther 41:3\u20138","journal-title":"Drug Metab Pers Ther"},{"key":"4955_CR10","doi-asserted-by":"publisher","first-page":"1561779","DOI":"10.3389\/fphar.2026.1721828","volume":"17","author":"LA Qui\u00f1ones","year":"2026","unstructured":"Qui\u00f1ones LA, Peralta S, Morales S, Dorado P, Llerena A (2026) Addressing genetic diversity and health inequities in Latin American pharmacogenomics: implications for precision medicine implementation. Front Pharmacol 17:1561779","journal-title":"Front Pharmacol"},{"key":"4955_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210\u2013216","journal-title":"Clin Pharmacol Ther"},{"key":"4955_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13699","volume":"17","author":"AJ Turner","year":"2024","unstructured":"Turner AJ, Haidar CE, Yang W, Boone EC, Offer SM, Empey PE, Haddad A, Tahir S, Scharer G, Broeckel U, Gaedigk A (2024) Updated DPYD HapB3 haplotype structure and implications for pharmacogenetic testing. Clin Transl Sci 17:e13699","journal-title":"Clin Transl Sci"},{"key":"4955_CR13","first-page":"13","volume":"4","author":"V Gonzalez-Covarrubias","year":"2024","unstructured":"Gonzalez-Covarrubias V, Cruz-Jaramilllo JL, Garc\u00eda-Mu\u00f1oz W (2024) Proceedings of Scientific Research Universidad An\u00e1huac. Proc Sci Res Univ An\u00e1huac Multidiscip J Healthc 4:13\u201374","journal-title":"Proc Sci Res Univ An\u00e1huac Multidiscip J Healthc"},{"key":"4955_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-025-00467-7","author":"MC Gil-Rodr\u00edguez","year":"2025","unstructured":"Gil-Rodr\u00edguez MC, Solano-Iturri JD, L\u00f3pez-Fern\u00e1ndez A, Castej\u00f3n N, Garc\u00eda-Alfonso P, Robles L, Fern\u00e1ndez-Salguero PM, Ayuso C, L\u00f3pez-Fern\u00e1ndez LA (2025) Discordance between HapB3 proxy and causal DPYD variants in Latin populations and implications for fluoropyrimidine toxicity prediction. Pharmacogenomics J. https:\/\/doi.org\/10.1038\/s41397-025-00467-7","journal-title":"Pharmacogenomics J"},{"key":"4955_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263\u2013265","journal-title":"Bioinformatics"},{"key":"4955_CR16","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1089\/dna.2020.5804","volume":"39","author":"K Lozano-Gonzalez","year":"2020","unstructured":"Lozano-Gonzalez K, Padilla-Rodr\u00edguez E, Texis T, Cort\u00e9s-Ram\u00edrez S, Barajas-Olmos F, Rodr\u00edguez-Dorantes M, Sober\u00f3n X, Gonz\u00e1lez-Covarrubias V (2020) Allele frequency of ACE2 intron variants and its association with blood pressure. DNA Cell Biol 39:2095\u20132101","journal-title":"DNA Cell Biol"},{"key":"4955_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000517462","volume":"106","author":"V Gonzalez-Covarrubias","year":"2021","unstructured":"Gonzalez-Covarrubias V, S\u00e1nchez-Ibarra H, Lozano-Gonzalez K, Villica\u00f1a S, Texis T, Rodr\u00edguez-Dorantes M, Cort\u00e9s-Ram\u00edrez S, Lavalle-Gonzalez F, Sober\u00f3n X, Barrera-Salda\u00f1a H (2021) Transporters, TBC1D4, and ARID5B variants to explain glycated hemoglobin variability in patients with type 2 diabetes. Pharmacology 106:588\u2013596","journal-title":"Pharmacology"},{"key":"4955_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/ph18050727","volume":"18","author":"S Otero-Torres","year":"2025","unstructured":"Otero-Torres S, Rodr\u00edguez-Mauriz R, Fort-Casamartina E, Mart\u00ednez-Lamas L, S\u00e1nchez-P\u00e9rez R, L\u00f3pez-L\u00f3pez R, Vizca\u00edno-Rodr\u00edguez J, Carracedo \u00c1 (2025) DPYD genotyping, fluoropyrimidine dosage and toxicity: an umbrella review of systematic reviews. Pharmaceuticals (Basel) 18:727","journal-title":"Pharmaceuticals (Basel)"},{"key":"4955_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12981-5","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, de Almeida Barbosa AB, Sano VKT, Kelly FA, Burbano RMR (2024) Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis. BMC Cancer 24:1210","journal-title":"BMC Cancer"},{"key":"4955_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2024.103706","volume":"38","author":"J Keen","year":"2025","unstructured":"Keen J, McDermott JH, Aguilar-Martinez E, Newman WG (2025) Pharmacogenetics: DPYD and prevention of toxicity. Clin Oncol (R Coll Radiol) 38:103706","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"4955_CR21","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/annonc\/mdp046","volume":"20","author":"S Afzal","year":"2009","unstructured":"Afzal S, Jensen SA, Vainer B, S\u00f8rensen JB, R\u00f8mer MU, Pfeiffer P, Qvortrup C, Linnemann D, Larsen FO, Laurberg S, Jakobsen A (2009) Methylenetetrahydrofolate reductase polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 20:1660\u20131666","journal-title":"Ann Oncol"},{"key":"4955_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3346\/jkms.2013.28.8.1129","volume":"28","author":"JG Shin","year":"2013","unstructured":"Shin JG, Cheong HS, Kim JY, Kim LH, Lee KA, Kang HJ, Kim H, Kim Y, Jung S, Kang B, Lee S, Kim JW (2013) Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups. J Korean Med Sci 28:1129\u20131134","journal-title":"J Korean Med Sci"},{"key":"4955_CR23","unstructured":"U.S. Food and Drug Administration. Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5-FU treatment. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/ Accessed December 12, 2025."},{"key":"4955_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-023-00322-x","volume":"24","author":"R Larrue","year":"2024","unstructured":"Larrue R, Fellah S, Hennart B, Sabaouni N, Boukrout N, Van der Hauwaert C, Delage C, Cheok M, Perrais M, Cauffiez C, Allorge D, Pottier N (2024) Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. Pharmacogenomics J 24:1\u20139","journal-title":"Pharmacogenomics J"},{"key":"4955_CR25","unstructured":"Dean L, Kane M (2025) Fluorouracil therapy and DPYD genotype. In: Medical Genetics Summaries. National Center for Biotechnology Information"},{"key":"4955_CR26","unstructured":"PharmGKB. Annotation of CPIC guideline for capecitabine and DPYD. PharmGKB website. https:\/\/www.pharmgkb.org\/ Accessed December 12 2025."},{"key":"4955_CR27","doi-asserted-by":"publisher","first-page":"17928","DOI":"10.1038\/s41598-022-22914-6","volume":"12","author":"S Ohnami","year":"2022","unstructured":"Ohnami S, Naruoka A, Isaka M, Yoshida R, Kato T, Kuniyoshi R, Sugaya A, Ono A, Ishizuka T, Arai M, Nishida Y, Mori K, Kazuno S, Kume H, Fukui T, Matsumoto S, Yokose T, Hosomi Y (2022) Comparison of genetic susceptibility to lung adenocarcinoma and squamous cell carcinoma using a panel for drug-metabolizing enzyme genes. Sci Rep 12:17928","journal-title":"Sci Rep"},{"key":"4955_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cpt.685","volume":"102","author":"Q Nie","year":"2017","unstructured":"Nie Q, Shrestha S, Tapper EE, Jones MR, Nicora CD, Hornburg D, Raftery D, Ho RJY, O\u2019Donnell PV, Baker KS, Monnat RJ Jr, Salomonis N, McDonald GB, Thummel KE (2017) Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther 102:662\u2013670","journal-title":"Clin Pharmacol Ther"},{"key":"4955_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/FTD.0b013e318040b1fe","volume":"29","author":"HJ Cho","year":"2007","unstructured":"Cho HJ, Park YS, Kang WK, Kim JW, Lee SY (2007) Thymidylate synthase and dihydropyrimidine dehydrogenase polymorphisms in the Korean population for prediction of 5-FU-associated toxicity. Ther Drug Monit 29:190\u2013196","journal-title":"Ther Drug Monit"},{"key":"4955_CR30","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2217\/14622416.8.11.1561","volume":"8","author":"MC Etienne-Grimaldi","year":"2007","unstructured":"Etienne-Grimaldi MC, Francoual M, Formento JL, Milano G (2007) Methylenetetrahydrofolate reductase variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics 8:1561\u20131576","journal-title":"Pharmacogenomics"},{"key":"4955_CR31","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/bjc.2013.262","volume":"108","author":"A Loganayagam","year":"2013","unstructured":"Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM (2013) Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 108:2505\u20132515","journal-title":"Br J Cancer"},{"key":"4955_CR32","doi-asserted-by":"publisher","first-page":"2144443","DOI":"10.1155\/2022\/2144443","volume":"2022","author":"Y Fan","year":"2022","unstructured":"Fan Y, Wu L, Zhuang W, Imig JD (2022) Methylenetetrahydrofolate reductase gene rs1801133 and rs1801131 polymorphisms and essential hypertension risk: a comprehensive analysis. Cardiovasc Ther 2022:2144443","journal-title":"Cardiovasc Ther"},{"key":"4955_CR33","doi-asserted-by":"publisher","first-page":"1184523","DOI":"10.3389\/fphar.2023.1184523","volume":"14","author":"A Maslarinou","year":"2023","unstructured":"Maslarinou A, Manolopoulos VG, Ragia G (2023) Pharmacogenetic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol 14:1184523","journal-title":"Front Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04955-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:42:58Z","timestamp":1789630978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04955-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4955"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04955-0","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board and Research Ethics Committee of the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n (INCMNSZ), Mexico City, Mexico, and was conducted in accordance with the Declaration of Helsinki and applicable local regulations.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to enrollment in the study.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was an observational cohort study and was not registered as a clinical trial.","order":4,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"104"}}